Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portage Biotech Inc.

www.portagebiotech.com

Latest From Portage Biotech Inc.

Deal Watch: Harbour Expands Horizons Beyond China

Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.

Deals Business Strategies

Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study

Top-line results from the Phase IIIb LIBERTY study are positive regarding primary and secondary endpoints, and could put erenumab ahead of other CGRP antagonists in difficult-to-treat migraine, as this novel class of agents nears the market for migraine prevention.

Neurology Clinical Trials

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Bontan Corp. Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Portage Biotech Inc.
  • Senior Management
  • Ian Walters, MD, CEO
    Kamlesh Shah, CFO
  • Contact Info
  • Portage Biotech Inc.
    Phone: (416) 929-1806
    47 Avenue Rd.
    Ste. 200
    Toronto, M5R 2G3
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register